ReCode Therapeutics

📍 Menlo Park, California & Dallas, Texas, United States🗓 Founded 2015👥 130 employees💰 Last funded Jun 2022
Biotechnology Research🌐 recodetx.com
Website LinkedIn
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in ReCode Therapeutics?
ReCode Therapeutics has 2 investors on record on gritt.io and 2 late-stage investors.
When did ReCode Therapeutics last raise funding?
The most recent investment in ReCode Therapeutics recorded on gritt.io was in June 2022.
When was ReCode Therapeutics founded?
ReCode Therapeutics was founded in 2015.
What industry is ReCode Therapeutics in?
ReCode Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ReCode Therapeutics based?
ReCode Therapeutics is headquartered in Menlo Park, California & Dallas, Texas, United States.